RASA1
RASA1 (Ras GTPase-activating protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Colorectal cancer, Lung cancer and 4 more.
Overview
GTPase-activating protein (GAP) that stimulates the intrinsic GTPase activity of Ras proteins, such as NRAS, facilitating their transition from the active GTP-bound state to the inactive GDP-bound state, thereby terminating Ras signalling.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Trametinib. Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes literature 0.94, animal model 0.42, genetic association 0.28, somatic mutation 0.91). IntOGen calls it a driver in 2 cohorts (0 activating, 2 loss-of-function), covering Head and Neck Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · RASA1 (Ras GTPase-activating protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Colorectal cancer, Lung cancer and 4 more.
- 1 · What it is
RASA1 (Ras GTPase-activating protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Colorectal cancer, Lung cancer and 4 more.
- 2 · What goes wrong in cancer
GTPase-activating protein (GAP) that stimulates the intrinsic GTPase activity of Ras proteins, such as NRAS, facilitating their transition from the active GTP-bound state to the inactive GDP-bound state, thereby terminating Ras signalling.
- 3 · How drugs use it
No product in this corpus aims at RASA1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:9871 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P20936 (protein name, function text, keywords and locations (REST API)); CIViC gene RASA1 (1 evidence items, 0 assertions, 1 variants; diseases: Lung Non-small Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000145715 (association with cancer (MONDO_0004992) 0.77; per-cancer scores at or above 0.5: colorectal cancer 0.53, gastric cancer 0.51, skin cancer 0.52, basal cell carcinoma 0.52, lung cancer 0.53 (GraphQL API, CC0)); IntOGen RASA1 (driver in 2 cohorts (Act 0, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
GTPase-activating protein (GAP) that stimulates the intrinsic GTPase activity of Ras proteins, such as NRAS, facilitating their transition from the active GTP-bound state to the inactive GDP-bound state, thereby terminating Ras signalling. Location: Cytoplasm (UniProt). Locus 5q14.3 (HGNC).
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Colorectal cancer: Open Targets association 0.53 with colorectal cancer (MONDO_0005575)
- Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903)
- Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.51 with gastric cancer (MONDO_0001056)
- Non-small-cell lung cancer: CIViC evidence names this disease; IntOGen driver in 1 cohort (LUSC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"RASA1" OR ABSTRACT:"RASA1" OR TITLE:"RAS p21 protein activator 1" OR ABSTRACT:"RAS p21 protein activator 1" OR TITLE:"Ras GTPase-activating protein 1" OR ABSTRACT:"Ras GTPase-activating protein 1" OR TITLE:"CM-AVM" OR ABSTRACT:"CM-AVM" OR TITLE:"p120GAP" OR ABSTRACT:"p120GAP" OR TITLE:"p120RASGAP" OR ABSTRACT:"p120RASGAP") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RASA1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetBARD1
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetCIITA
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetRICTOR
Shares Lung cancer (all types), Skin cancer (all types), CIViC, Gastric & gastro-oesophageal junction cancer.
- TargetLRP1B
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetCRLF2
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetFUBP1
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetABL2
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.